25th Mar 2019 18:09
LONDON (Alliance News) - Biopharmaceutical firm PureTech Health PLC on Monday said that its affiliate Gelesis reported positive tests results on two products, Gel-B (GS300) and Gelesis100.
Gelesis presented data showing that Gel-B repairs the seal between intestinal epithelial cells helping restore the gut barrier after damage, PureTech Health said.
"This finding supports the potential application of Gel-B across diseases affected by gut barrier dysfunction, such as inflammatory bowel disease, type 2 diabetes, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis," the company added.
Furthermore, Gelesis presented data supporting a positive effect of its lead product Gelesis100 on people with prediabetes, untreated diabetes, and elevated insulin resistance.
Gelesis100 is a superabsorbent hydrogel in development for the potential treatment of overweight and obesity. Data showed that patients treated with the gel has six times higher odds of achieving weight loss of over 10% in six months compared to placebo.
Gelesis was co-founded by PureTech Health.
PureTech shares closed up 2.8% at 167.00 pence each.
Related Shares:
PureTech